<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555750</url>
  </required_header>
  <id_info>
    <org_study_id>BWH-HRC-2005-P-001997</org_study_id>
    <secondary_id>ESRC0004</secondary_id>
    <secondary_id>M01RR002635</secondary_id>
    <nct_id>NCT00555750</nct_id>
  </id_info>
  <brief_title>Sleep Loss and Mechanisms of Impaired Glucose Metabolism</brief_title>
  <official_title>The Effects of Eszopiclone Treatment (3mg for Two Months) to Counteract the Adverse Metabolic Consequences of Primary Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effects of sleep and eszopiclone, a drug that helps
      people sleep, on how the body processes glucose (sugar). Eszopiclone is approved by the U.S.
      Food and Drug Administration (FDA) for sale for the treatment of insomnia. It is marketed in
      the United States as LUNESTA.

      Main Hypothesis: Primary insomnia is associated with impairments of glucose metabolism that
      can be reversed by two months of eszopiclone for the primary insomnia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insomnia is the most common sleep disorder, affecting nearly one-third of all adults in any
      given year, and chronically affecting 10-15% of the adult population. Reduced sleep time,
      independent of insomnia, has been associated with a variety of deleterious long term effects,
      including an increased risk of incident myocardial infarction and symptomatic diabetes.
      Chronic partial sleep loss or insomnia may impair glucose metabolism in the short term and
      are associated with the development of diabetes in the long term. Although the extent of
      sleep loss is more acute in the laboratory-based 'sleep debt' studies of healthy volunteers,
      chronic primary insomnia patients exhibit 'hyperarousal' (hypercortisolemia in the afternoon
      and evening, accelerated metabolism) similar to that seen with acute sleep deprivation. In
      addition, degradations of sleep quantity and quality in primary insomnia have been attributed
      to cognitive and somatic hyperarousal in the sleep setting. study examines and quantifies in
      adult men and women the link between primary insomnia and impaired glucose tolerance. This
      study examines the extent which adequate treatment of primary insomnia reverses impairments
      of glucose metabolism. If abnormalities of glucose metabolism are reversible, this study will
      demonstrate the importance of treatment of chronic primary insomnia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test</measure>
    <time_frame>baseline and 2 months post-treatment</time_frame>
    <description>Difference in glucose tolerance (Kg) in response to insulin-modified intravenous glucose tolerance test. Glucose tolerance was calculated as the slope of the natural log of declining glucose values from minute 5 to minute 19 post-infusion. By convention, this negative slope is multiplied by -1, in other words, expressed as a rate of disposal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Insulin Response to Glucose (AIRg)</measure>
    <time_frame>baseline and 2 months post-treatment</time_frame>
    <description>Change over two months in 1st phase Insulin secretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Sensitivity (SI)</measure>
    <time_frame>baseline and 2 months post-treatment</time_frame>
    <description>Insulin sensitivity index (SI) &quot;was defined in quantitative terms as the effect of insulin to catalyse the disappearance of glucose from plasma.&quot; [R. Bergman, Horm Res 2005;64(suppl 3):8-15].
SI calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glucose Effectiveness (SG)</measure>
    <time_frame>baseline and 2 months post-treatment</time_frame>
    <description>Glucose effectiveness was defined as &quot;the ability of glucose itself to enhance its own disappearance independent of an increment in insulin.&quot; [R. Bergman, Horm Res 2005;64(suppl 3):8-15].
SG calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c Levels</measure>
    <time_frame>baseline and 2 months post-treatment</time_frame>
    <description>Difference in HbA1c levels following two months treatment with eszopiclone versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-Treatment Leptin Levels</measure>
    <time_frame>baseline</time_frame>
    <description>Leptin Levels prior to two months treatment with eszopiclone or placebo, measure after an overnight fast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Leptin Levels</measure>
    <time_frame>two months post-treatment</time_frame>
    <description>Leptin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-treatment Ghrelin Levels</measure>
    <time_frame>baseline</time_frame>
    <description>Ghrelin levels prior to two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment Ghrelin Levels</measure>
    <time_frame>2 months post-treatment</time_frame>
    <description>Ghrelin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Subjective Sleepiness as Measured on the Karolinska Sleepiness Scale (KSS)</measure>
    <time_frame>baseline and 2 months post-treatment</time_frame>
    <description>At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery including the Karolinska Sleepiness Scale (KSS) every three hours during wake periods. KSS is a single-item scale of sleepiness on a scale from 1 (&quot;very alert&quot;) to 9 (&quot;very sleepy, fighting sleep, an effort to keep awake&quot;). Subjective sleepiness was defined as mean deviation from baseline KSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Lapses of Attention</measure>
    <time_frame>baseline and 2 months post-treatment</time_frame>
    <description>At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery every three hours during wake periods. The battery included the Psychomotor Vigilance Task (PVT). The PVT involved a 10-minute visual reaction time (RT) performance test in which the subject was instructed to maintain the fastest possible RT to a simple visual stimulus. Lapses of attention refer to the number of times the subject failed to respond to the signal within 500ms. Mean lapses per test across 6 tests given a 4 hour intervals during normal waking hours (and not during the IVGTT) during the 30-hr were compared for the post-treatment visit as the absolute deviation from the baseline mean lapses/test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Sleep Time as Reported in Sleep Diaries</measure>
    <time_frame>baseline and 2 months post-treatment</time_frame>
    <description>Total sleep time reported on sleep diaries prior to treatment with 3mg eszopiclone or placebo. Change defined as baseline minus post-treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Sleep Time Measured by PSG</measure>
    <time_frame>baseline and 2 months post-treatment</time_frame>
    <description>Change (baseline minus post-treatment) in total sleep time measured by polysomnography after two months treatment with 3mg eszopiclone or placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>eszopiclone (3mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>active medication (eszopiclone 3mg tablet) by mouth nightly 30 min before bed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>identical placebo tablet by mouth nightly 30 min before bed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eszopiclone</intervention_name>
    <description>3mg tablet, by mouth nightly 30 min before bed, for two months</description>
    <arm_group_label>eszopiclone (3mg)</arm_group_label>
    <other_name>Lunesta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 25-55

          -  Complaint of insomnia of at least 6 months duration

          -  DSM-IV diagnosis of Primary Insomnia

          -  Sleep diary: mean Total Sleep Time &lt; 6 hours and a mean total wake time (sleep latency
             + wake after sleep onset) of greater than 60 minutes (in previous 14 days as recorded
             on sleep diary)

          -  A willingness to comply with study procedures

          -  If of child-bearing potential, using a medically-accepted method of birth control,
             including abstinence, barrier method with spermicide, steroidal contraceptive (oral,
             transdermal, implanted, and injected) in conjunction with a barrier method, and
             intrauterine device [IUD])

        Exclusion Criteria:

          -  Current diagnosis of DSM-IV Axis I disorder other than Primary Insomnia

          -  Regular treatment (more than 1 time/week) with CNS active medication within 1 month of
             fist inpatient visit

          -  Treatment with medications that interfere with glucose metabolism including
             anti-diabetic medications or steroidal contraceptives

          -  Uncontrolled medical illness that would interfere with participation in the study

          -  Body Mass Index &gt;32 or &lt;19.8

          -  Current symptoms or diagnosis of any moderate to severe sleep disorder other than
             insomnia

          -  No menopausal or peri-menopausal symptoms that disrupt sleep

          -  Pregnant, lactating or planning to become pregnant

          -  Consumption of &gt; 2 caffeinated beverages per day (including coffee, tea and/or other
             caffeine-containing beverages or food) during 3 weeks prior to the start of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Winkelman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital, Division of Sleep Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ayas NT, White DP, Al-Delaimy WK, Manson JE, Stampfer MJ, Speizer FE, Patel S, Hu FB. A prospective study of self-reported sleep duration and incident diabetes in women. Diabetes Care. 2003 Feb;26(2):380-4.</citation>
    <PMID>12547866</PMID>
  </reference>
  <reference>
    <citation>Ayas NT, White DP, Manson JE, Stampfer MJ, Speizer FE, Malhotra A, Hu FB. A prospective study of sleep duration and coronary heart disease in women. Arch Intern Med. 2003 Jan 27;163(2):205-9.</citation>
    <PMID>12546611</PMID>
  </reference>
  <reference>
    <citation>Beck-Nielsen H, Henriksen JE, Alford F, Hother-Nielson O. In vivo glucose metabolism, insulin secretion and, insulin action in Europids with non-insulin-dependent diabetes mellitus (NIDDM) and their first-degree relatives. Diabet Med. 1996 Sep;13(9 Suppl 6):S78-84. Review.</citation>
    <PMID>8894487</PMID>
  </reference>
  <reference>
    <citation>Belenky G, Wesensten NJ, Thorne DR, Thomas ML, Sing HC, Redmond DP, Russo MB, Balkin TJ. Patterns of performance degradation and restoration during sleep restriction and subsequent recovery: a sleep dose-response study. J Sleep Res. 2003 Mar;12(1):1-12.</citation>
    <PMID>12603781</PMID>
  </reference>
  <reference>
    <citation>Boyne MS, Saudek CD. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes. Diabetes Care. 1999 Apr;22 Suppl 3:C45-53. Review.</citation>
    <PMID>10189562</PMID>
  </reference>
  <reference>
    <citation>Buxton OM, Spiegel K and Van Cauter E. Modulation of endocrine function and metabolism by sleep and sleep loss. In: Sleep Medicine, edited by Lee-Chiong M, Carskadon M and Sateia M. Philadelphia: Hanley &amp; Belfus, Inc., 2002, p. 59-69.</citation>
  </reference>
  <reference>
    <citation>Buysse DJ, Jarrett DB, Miewald JM, Kupfer DJ, Greenhouse JB. Minute-by-minute analysis of REM sleep timing in major depression. Biol Psychiatry. 1990 Nov 15;28(10):911-25.</citation>
    <PMID>2268693</PMID>
  </reference>
  <reference>
    <citation>Czeisler CA, Winkelman JW and Richardson GS. Disorders of sleep and circadian rhythms. In: Harrison's Principles of Internal Medicine, edited by Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL and Jameson JL. New York: McGraw-Hill,Inc., 2000, p. 1-78.</citation>
  </reference>
  <reference>
    <citation>Dijk DJ, Duffy JF, Czeisler CA. Circadian and sleep/wake dependent aspects of subjective alertness and cognitive performance. J Sleep Res. 1992 Jun;1(2):112-7.</citation>
    <PMID>10607036</PMID>
  </reference>
  <reference>
    <citation>Dinges DF, Kribbs NB, Bates BL and Carlin MM. A very brief probed-recall memory task: Sensitivity to sleep loss. Sleep Res 22: 330, 1993.</citation>
  </reference>
  <reference>
    <citation>Dinges DF and Powell JW. Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. Behavior Research Methods, Instruments &amp; Computers 17: 652-655, 1985.</citation>
  </reference>
  <reference>
    <citation>Gillberg M, Kecklund G, Akerstedt T. Relations between performance and subjective ratings of sleepiness during a night awake. Sleep. 1994 Apr;17(3):236-41.</citation>
    <PMID>7939123</PMID>
  </reference>
  <reference>
    <citation>Gottlieb DJ, Punjabi NM, Newman AB, Resnick HE, Redline S, Baldwin CM, Nieto FJ. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. 2005 Apr 25;165(8):863-7.</citation>
    <PMID>15851636</PMID>
  </reference>
  <reference>
    <citation>Hoddes E, Dement WC and Zarcone V. The development and use of the Stanford Sleepiness Scale (SSS). Psychophysiol 9: 150, 1971.</citation>
  </reference>
  <reference>
    <citation>King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998 Sep;21(9):1414-31.</citation>
    <PMID>9727886</PMID>
  </reference>
  <reference>
    <citation>King H, Zimmet P. Trends in the prevalence and incidence of diabetes: non-insulin-dependent diabetes mellitus. World Health Stat Q. 1988;41(3-4):190-6.</citation>
    <PMID>2466380</PMID>
  </reference>
  <reference>
    <citation>Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4;288(21):2709-16.</citation>
    <PMID>12460094</PMID>
  </reference>
  <reference>
    <citation>Nilsson PM, Rööst M, Engström G, Hedblad B, Berglund G. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care. 2004 Oct;27(10):2464-9.</citation>
    <PMID>15451917</PMID>
  </reference>
  <reference>
    <citation>Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry. 1997 Oct;154(10):1417-23.</citation>
    <PMID>9326825</PMID>
  </reference>
  <reference>
    <citation>Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999 Oct 23;354(9188):1435-9.</citation>
    <PMID>10543671</PMID>
  </reference>
  <reference>
    <citation>Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004 Dec 7;141(11):846-50.</citation>
    <PMID>15583226</PMID>
  </reference>
  <reference>
    <citation>Van Dongen HP, Maislin G, Mullington JM, Dinges DF. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep. 2003 Mar 15;26(2):117-26. Erratum in: Sleep. 2004 Jun 15;27(4):600.</citation>
    <PMID>12683469</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2007</study_first_submitted>
  <study_first_submitted_qc>November 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2007</study_first_posted>
  <results_first_submitted>May 21, 2013</results_first_submitted>
  <results_first_submitted_qc>July 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2013</results_first_posted>
  <last_update_submitted>November 15, 2013</last_update_submitted>
  <last_update_submitted_qc>November 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>John W. Winkelman, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>metabolism</keyword>
  <keyword>insulin</keyword>
  <keyword>glucose</keyword>
  <keyword>actigraphy</keyword>
  <keyword>diary</keyword>
  <keyword>volumetry</keyword>
  <keyword>GABA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eszopiclone</title>
          <description>nightly active medication (eszopiclone, 3 mg tablet) oral administration ~30 min before bed</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>nightly placebo (identical tablet to active medication) oral administration ~30 min before bed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>active medication administration nightly before bed</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>nightly administration of placebo before bed</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test</title>
        <description>Difference in glucose tolerance (Kg) in response to insulin-modified intravenous glucose tolerance test. Glucose tolerance was calculated as the slope of the natural log of declining glucose values from minute 5 to minute 19 post-infusion. By convention, this negative slope is multiplied by -1, in other words, expressed as a rate of disposal.</description>
        <time_frame>baseline and 2 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test</title>
          <description>Difference in glucose tolerance (Kg) in response to insulin-modified intravenous glucose tolerance test. Glucose tolerance was calculated as the slope of the natural log of declining glucose values from minute 5 to minute 19 post-infusion. By convention, this negative slope is multiplied by -1, in other words, expressed as a rate of disposal.</description>
          <units>%/min, slope of natural log glucose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".33" spread=".94"/>
                    <measurement group_id="O2" value="-0.10" spread=".42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Insulin Response to Glucose (AIRg)</title>
        <description>Change over two months in 1st phase Insulin secretion</description>
        <time_frame>baseline and 2 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Insulin Response to Glucose (AIRg)</title>
          <description>Change over two months in 1st phase Insulin secretion</description>
          <units>mU*l^-1*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0" spread="269.0"/>
                    <measurement group_id="O2" value="25.1" spread="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Sensitivity (SI)</title>
        <description>Insulin sensitivity index (SI) &quot;was defined in quantitative terms as the effect of insulin to catalyse the disappearance of glucose from plasma.&quot; [R. Bergman, Horm Res 2005;64(suppl 3):8-15].
SI calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)</description>
        <time_frame>baseline and 2 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity (SI)</title>
          <description>Insulin sensitivity index (SI) &quot;was defined in quantitative terms as the effect of insulin to catalyse the disappearance of glucose from plasma.&quot; [R. Bergman, Horm Res 2005;64(suppl 3):8-15].
SI calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)</description>
          <units>mU/l)^-1*min^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="2.57"/>
                    <measurement group_id="O2" value="0.05" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glucose Effectiveness (SG)</title>
        <description>Glucose effectiveness was defined as &quot;the ability of glucose itself to enhance its own disappearance independent of an increment in insulin.&quot; [R. Bergman, Horm Res 2005;64(suppl 3):8-15].
SG calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)</description>
        <time_frame>baseline and 2 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glucose Effectiveness (SG)</title>
          <description>Glucose effectiveness was defined as &quot;the ability of glucose itself to enhance its own disappearance independent of an increment in insulin.&quot; [R. Bergman, Horm Res 2005;64(suppl 3):8-15].
SG calculated using Bergman's Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)</description>
          <units>min^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.004"/>
                    <measurement group_id="O2" value="0.001" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c Levels</title>
        <description>Difference in HbA1c levels following two months treatment with eszopiclone versus placebo</description>
        <time_frame>baseline and 2 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c Levels</title>
          <description>Difference in HbA1c levels following two months treatment with eszopiclone versus placebo</description>
          <units>percentage of glycosylation</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".03" spread=".11"/>
                    <measurement group_id="O2" value="-.09" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-Treatment Leptin Levels</title>
        <description>Leptin Levels prior to two months treatment with eszopiclone or placebo, measure after an overnight fast</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-Treatment Leptin Levels</title>
          <description>Leptin Levels prior to two months treatment with eszopiclone or placebo, measure after an overnight fast</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.99" spread="3.63"/>
                    <measurement group_id="O2" value="16.53" spread="11.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Leptin Levels</title>
        <description>Leptin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast</description>
        <time_frame>two months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Leptin Levels</title>
          <description>Leptin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.49" spread="4.33"/>
                    <measurement group_id="O2" value="15.28" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-treatment Ghrelin Levels</title>
        <description>Ghrelin levels prior to two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-treatment Ghrelin Levels</title>
          <description>Ghrelin levels prior to two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573.14" spread="336.50"/>
                    <measurement group_id="O2" value="648.41" spread="230.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-treatment Ghrelin Levels</title>
        <description>Ghrelin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast</description>
        <time_frame>2 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Post-treatment Ghrelin Levels</title>
          <description>Ghrelin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544.95" spread="273.65"/>
                    <measurement group_id="O2" value="670.94" spread="180.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Subjective Sleepiness as Measured on the Karolinska Sleepiness Scale (KSS)</title>
        <description>At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery including the Karolinska Sleepiness Scale (KSS) every three hours during wake periods. KSS is a single-item scale of sleepiness on a scale from 1 (&quot;very alert&quot;) to 9 (&quot;very sleepy, fighting sleep, an effort to keep awake&quot;). Subjective sleepiness was defined as mean deviation from baseline KSS.</description>
        <time_frame>baseline and 2 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Subjective Sleepiness as Measured on the Karolinska Sleepiness Scale (KSS)</title>
          <description>At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery including the Karolinska Sleepiness Scale (KSS) every three hours during wake periods. KSS is a single-item scale of sleepiness on a scale from 1 (&quot;very alert&quot;) to 9 (&quot;very sleepy, fighting sleep, an effort to keep awake&quot;). Subjective sleepiness was defined as mean deviation from baseline KSS.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.42"/>
                    <measurement group_id="O2" value="0.38" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Lapses of Attention</title>
        <description>At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery every three hours during wake periods. The battery included the Psychomotor Vigilance Task (PVT). The PVT involved a 10-minute visual reaction time (RT) performance test in which the subject was instructed to maintain the fastest possible RT to a simple visual stimulus. Lapses of attention refer to the number of times the subject failed to respond to the signal within 500ms. Mean lapses per test across 6 tests given a 4 hour intervals during normal waking hours (and not during the IVGTT) during the 30-hr were compared for the post-treatment visit as the absolute deviation from the baseline mean lapses/test.</description>
        <time_frame>baseline and 2 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Lapses of Attention</title>
          <description>At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery every three hours during wake periods. The battery included the Psychomotor Vigilance Task (PVT). The PVT involved a 10-minute visual reaction time (RT) performance test in which the subject was instructed to maintain the fastest possible RT to a simple visual stimulus. Lapses of attention refer to the number of times the subject failed to respond to the signal within 500ms. Mean lapses per test across 6 tests given a 4 hour intervals during normal waking hours (and not during the IVGTT) during the 30-hr were compared for the post-treatment visit as the absolute deviation from the baseline mean lapses/test.</description>
          <units>lapses of attention</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.49"/>
                    <measurement group_id="O2" value="0.07" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Sleep Time as Reported in Sleep Diaries</title>
        <description>Total sleep time reported on sleep diaries prior to treatment with 3mg eszopiclone or placebo. Change defined as baseline minus post-treatment).</description>
        <time_frame>baseline and 2 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Sleep Time as Reported in Sleep Diaries</title>
          <description>Total sleep time reported on sleep diaries prior to treatment with 3mg eszopiclone or placebo. Change defined as baseline minus post-treatment).</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".58" spread=".36"/>
                    <measurement group_id="O2" value=".09" spread=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Sleep Time Measured by PSG</title>
        <description>Change (baseline minus post-treatment) in total sleep time measured by polysomnography after two months treatment with 3mg eszopiclone or placebo</description>
        <time_frame>baseline and 2 months post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>active medication administration nightly before bed</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nightly administration of placebo before bed</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Sleep Time Measured by PSG</title>
          <description>Change (baseline minus post-treatment) in total sleep time measured by polysomnography after two months treatment with 3mg eszopiclone or placebo</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="25.5"/>
                    <measurement group_id="O2" value="-6.4" spread="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>active medication administration nightly before bed</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>nightly administration of placebo before bed</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Unpleasant Taste</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Burning at infusion site</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Puncture Site Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injection pressure sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vasovagal syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Venipuncture site bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstruation with increased bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. John Winkelman, MD, PhD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-278-0061</phone>
      <email>jwwinkelman@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

